INS and type 2 diabetes mellitus: Although T2D in Japan and other East Asian countries is primarily characterized by lower levels of obesity and impaired insulin secretion compared to Western populations (3), GLP-1 receptor agonists are increasingly used among younger individuals with type 2 diabetes who are overweight or obese in these regions.